论文部分内容阅读
据统计表明,我国儿童约占总人口数的20%,但属于他们的药物只占总药品数的2%。而阻碍儿童药物的生产的主要因素之一就是儿童药物不良反应临床试验水平一直没能得到有效的突破。随着儿童疾病的不断增多,人们对于这一特殊群体的身心健康的关注度越来越大,如何有效的做好儿童疾病的治疗,如何保障儿童疾病患者在治疗过程中药物使用的安全性,如何在儿童患者能够在接受药物治疗中最小化的发生不良反应,这都是我们相关科学医疗工作者为之努力攻克的难题,也是我们社会各界所关注的重中之重。在这样的形式背景下,进行有效的儿童药物不良反应临床试验成为了保障儿童群体使用药物安全的一大保障,也是解决这一问题的有效途径,因此,本文就从儿童药物不良反应临床实验这一方向进行一番探究。
Statistics show that children account for about 20% of the total population in our country, but only 2% of the total drugs belong to them. And one of the main factors hindering the production of children’s medicines is that the clinical trial of children’s adverse drug reactions has not been able to effectively break through. With the increasing number of children’s diseases, people pay more and more attention to the physical and mental health of this special group, how to effectively treat children’s diseases, how to protect the safety of children’s diseases in the course of treatment, How to minimize the occurrence of adverse reactions in pediatric patients when receiving medication is a difficult problem that our relevant scientific medical workers strive to overcome. It is also the most important concern of all sectors of our society. In such a formal context, effective clinical trials of adverse drug reactions in children have become a major safeguard to ensure the safety of children’s use of drugs and an effective way to solve this problem. Therefore, this article starts with a clinical trial of children’s adverse drug reactions One way to explore.